San Francisco-based Viz.ai pharma announced that the company is launching its artificial intelligence-based molecules which allow for better management of pulmonary embolism and aortic disease. 

Pulmonary embolism is mostly caused by blood clots that travel to the lungs and block the pathway in the pulmonary arteries. The company said that the new AI molecules will identify the suspected pulmonary embolism in under 2 minutes. 

The company also added that the molecules use deep learning to identify the diseases. Medical researchers have expressed hope that the new device will reduce the diagnosis time and save lives under critical conditions.